InvestorsHub Logo
Followers 59
Posts 2025
Boards Moderated 1
Alias Born 05/07/2003

Re: petermic post# 1868

Thursday, 10/22/2009 1:23:21 PM

Thursday, October 22, 2009 1:23:21 PM

Post# of 64411
OK, so XCHO has exclusive rights to market Cobroxin in the U.S. Is this true?

Why did NPHC sell those rights to XCHO? XCHO doesn't appear to have any particular advantages - total sales last quarter was $13,500. Total assets are $1,050,000.

Here is how XCHO describes itself - "XenaCare Holdings, Inc. (the “Company”, “XenaCare”, “XC Holdings”, “we”, “us” or “our”) was organized under the laws of Florida in June 2005 to formulate, market and distribute a line of clinical, life style performance and protective nutrition supplement products (“NSPs”)."

XCHO is a 12 cent stock with 50 million shares outstanding.
NPHC is a 45 cent stock with 220 million outstanding -

plus these new shares I guess: "On August 20, 2009, our Board of Directors authorized the offer and sale of our common stock at $0.08 per share. From September 1, 2009 through September 22, 2009, we sold 34,948,750 million common shares (the “Shares”) to 65 accredited investors for aggregate proceeds of $2,795,900."


doesn't make sense